Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Mohammad Movahedi¹, Elliot Hepworth², Angela Cesta³, Xiuying Li³, Claire Bombardier⁴ and Sibel Aydin⁵, and OBRI investogators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
Abstract Number: 2262 • ACR Convergence 2024
Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez Casas¹¹, Cilia Peralta Ginés¹², Miriam Retuerto Guerrero¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Ana Urruticoechea Arana²³, Sergi Ordoñez²⁴, Carmen González Montagut²⁵, Andrea García-Valle²⁶, Juan Ramón De Dios²⁷, María Martín López²⁸, Tomás Vázquez Rodríguez²⁹, Delia Fernández-Lozano³⁰, Ignacio Brana Abascal³¹, Rafael Benito Melero-Gonzalez³², Emilio Giner³³, Virginia Ruiz-Esquide³⁴, Clara Ventin Rodriguez³⁵, Marina Rodriguez³⁶, Pablo Andújar-Brazal³⁷, Julia Fernandez Melon²³, Lilian M. López-Núñez³⁸, JOSE RAMON LAMUA RIAZUELO³⁹, Anna Pamies Corts⁴⁰, Carlos Fernández Díaz⁴¹, Javier Loricera⁴², Diego Ferrer⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universitario San Agustín, Avilés, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Complejo Asistencial Universitario de León, Leon, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰Hospital Universitario de Donosti, Donosti, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital Son Espases, Palma, Spain, ²⁴Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁵Hospital Universitario de Valladolid, Valladolid, Spain, ²⁶Hospital General Río Carrión, Palencia, Spain, ²⁷Osakidetza, Vitoria, Spain, ²⁸General University Hospital of Ciudad Real, Ciudad de México, Spain, ²⁹Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³⁰Hospital Clínico Universitario de Valencia, Valencia, Spain, ³¹Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³²CHU Ourense, O Carballino, Spain, ³³Hospital Royo Villanova, Teruel, Spain, ³⁴Hospital Clinic de Barcelona, Barcelona, Spain, ³⁵Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁶Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁷Hospital Universitario Doctor Peset, Valencia, Spain, ³⁸Hospital Universitari Son Llàtzer, Palma, Spain, ³⁹Hospital Universitario del Henares, Madrid, Spain, ⁴⁰Hospital Verge de la Cinta, Tortosa, TARRAGONA, Spain, ⁴¹Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴³Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD. Our objective…
Abstract Number: 2280 • ACR Convergence 2024
Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
Peter C. Taylor¹, Kevin Lai², Hsin-Ta Wu², Jason Carlson², Diana Abdueva³, Signe Fransen⁴, Alan Kivitz⁵, Gordon Lam⁶ and David Chernoff⁷, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual Inc., Hayward, CA, ⁴Aqtual Inc., sf, CA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Matching most beneficial targeted therapy to rheumatoid arthritis (RA) patients with inadequate response or intolerance to current treatment is an important unmet clinical need. The…
Abstract Number: 2544 • ACR Convergence 2024
Spatial Transcriptomics Suggests Synovial Macrophage Niches Are Sexually Dimorphic in a Mouse Inflammatory Arthritis Model
Richard Bell¹, Ruoxi Yuan², Mary Huang², Ewurama Cann², Chao Yang², Franck Barrat¹ and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²HSS, New York, NY
Background/Purpose: Monocytes and Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq…
Abstract Number: 2672 • ACR Convergence 2024
Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial
Quirine Dumoulin¹, Doortje Krijbolder², Karen Visser³, Leroy Lard⁴ and Annette van der Helm-van Mil⁵, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Haga Hospital The Hague, Amsterdam, Netherlands, ⁴Haaglanden Medical Center The Hague, Leidschendam, Netherlands, ⁵LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Currently, prevention possibilities of developing ACPA-negative rheumatoid arthritis (RA) are unknown. Studying this is challenging because many ACPA-negative at-risk individuals have low risk of…
Abstract Number: 0044 • ACR Convergence 2024
Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes
Cankut Cubuk¹, Rachel Lau¹, Vinothini Rajeeve², Pedro Cutillas², Rebecca Hands¹, Liliane Fossati-Jimack¹, Anna Surace¹, Alessandra Nerviani¹, Felice Rivellese¹, Myles Lewis³ and Costantino Pitzalis⁴, and the R4RA Collaborative Group, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ²Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴QMUL, Bromley Kent, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an incurable autoimmune disease where response to therapy is heterogenous. Clinically indistinguishable RA patients can be classified histo-pathologically into three…
Abstract Number: 0061 • ACR Convergence 2024
Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
Joshua Sciurba¹, Daniel Kass¹, Eleanor Valenzi², John Sembrat², Robert Lafyatis³ and Dana Ascherman⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Transcriptional profiling represents a powerful tool for deciphering disease-relevant pathways and deriving functional biomarkers. Given the shared demographic, genetic, and clinico-epidemiologic features between rheumatoid…
Abstract Number: 0149 • ACR Convergence 2024
Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
Samuel Good¹, Bryant England² and Elizabeth Volkmann³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of Nebraska Medical Center, Omaha, NE, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Studies that evaluate experiences of living with rheumatoid arthritis (RA) have found that patients identify self-empowerment and a sense of control as important factors…
Abstract Number: 0229 • ACR Convergence 2024
An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Brittany Weber¹, Feng Liu², Mary Jeffway², Dana Weisenfeld², Gregory McDermott³, Elena Massarotti², Jonathan Coblyn², Michael Weinblatt⁴, Marcelo Di Carli², Damini Dey⁵ and Katherine Liao², ¹Brigham and Women's Hospital, DEDHAM, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Cedars-Sinai Medical Center, Los Angeles
Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population. In a prior study of RA patients with…
Abstract Number: 0423 • ACR Convergence 2024
Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Sabrina Hamroun¹, Grégoire Martin De Frémont², Nathalie Costedoat-chalumeau³, Marion couderc⁴, René-Marc Flipo⁵, Laure Gossec⁶, Christophe Richez⁷, Rakiba Belkhir⁸, Aline Frazier⁹, Valerie Devauchelle¹⁰, Hubert Marotte¹¹, Jérémie Sellam¹², Elisabeth Gervais¹³, Alban Deroux¹⁴, Cedric Lukas¹⁵, Emmanuelle Dernis¹⁶, Emmanuel Chatelus¹⁷, Véronique Le Guern¹⁸, Gaëlle Guettrot-Imbert¹⁹, Nathalie Lelong²⁰, Camille Le Ray²⁰, Raphaele Seror²¹ and Anna Molto²², and ENP 2021 and GR2 Study Groups, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, ³University Paris Cité, Paris, France, ⁴CHU de Clermont-Ferrand, Clermont-Ferrand, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France, ⁶Sorbonne Université, Paris, France, ⁷Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ⁹Lariboisière University Hospital, Paris, France, ¹⁰UBO, Brest, France, ¹¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹²Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ¹³University hospital, Poitiers, France, ¹⁴Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁵Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁶CH LE MANS, LE MANS, Pays de la Loire, France, ¹⁷Rheumatology department strasbourg, Strasbourg, France, ¹⁸APHP, Hôpital Cochin, Paris, ¹⁹Cochin Hospital, Paris, France, ²⁰University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, ²¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²²Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with RA is suggested in the literature in several…
Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Monique Bastidas¹, Lythou Yeo¹, Susie Magpantay¹, Judah Scott¹, Mike Zikry¹, Wayne Galdamez¹, Jane Yang² and Kelly Chun¹, ¹Labcorp, Calabasas, CA, ²LabCorp, Weston, MA
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
Abstract Number: 0481 • ACR Convergence 2024
Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex
Marina Dueñas¹, Juan Carlos Sáez¹, María Paula Álvarez², Patricia Quiroga¹, Maryia Nikitsina³, Rosario García-Vicuña², Ana Ortiz⁴, Isidoro González-Álvaro³ and Irene Llorente-Cubas⁴, ¹Servicio de Reumatología Hospital La Princesa, Madrid, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ³University Hospital La Princesa, Madrid, Madrid, Spain, ⁴Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: The prevalence of comorbidities is increased in patients with rheumatoid arthritis (RA) compared to the general population1, but their impact in the earlier stages…
Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Wanki Ho¹, Huaqun Zhu¹, Hua Ye¹, Dongdong Fu² and Xi Xu¹, ¹Peking University People's Hospital, Beijing, China, ²Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
Abstract Number: 0515 • ACR Convergence 2024
Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis
Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…
Abstract Number: 0533 • ACR Convergence 2024
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial
Maike Wientjes¹, Sadaf Atiqi², Gertjan Wolbink³, Michael Nurmohamed⁴, Maarten Boers⁵, Femke Hooijberg², Theo Rispens⁶, Annick De Vries⁶, Floris Loeff⁶, Ronald Van Vollenhoven⁷, Sofia Ramiro⁸, Noortje van Herwaarden⁹, Bart van den Bemt¹⁰ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Reade, Amsterdam, Netherlands, ³Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁵Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁶Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands, ⁹Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁰Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…

« Previous Page
1
…
3
4
5
6
7
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].